» Articles » PMID: 34403099

Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China

Overview
Journal Curr Med Sci
Specialty General Medicine
Date 2021 Aug 17
PMID 34403099
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma (NPC) from low-endemic regions of China who received definitive intensity-modulated radiation therapy (IMRT).

Methods: The clinical data from 608 patients with newly-diagnosed non-metastatic NPC who have received initial treatment at our cancer center from January, 2008 to December, 2013 were retrospectively reviewed. All patients received definitive IMRT, and 87.7% received platinum-based chemotherapy.

Results: The median follow-up duration was 51 months (follow-up rate, 98.5%; range, 10-106 months) for the entire cohort. The 5-year overall survival rate was 79.7%. The 5-year local relapse-free survival rate, regional relapse-free survival rate, distant metastasis-free survival rate and progression-free survival rate were 92.4%, 93.3%, 79.2% and 74.3%, respectively. A total of 153 patients had experienced treatment failure, with distant metastasis as the primary cause in 77.1% (118/153). Patients with T4 or N3 diseases had a significantly poorer prognosis than other subcategories. Stage T4 and N3 were closely associated with distant metastasis, with the metastatic rate of 29.3% and 45.5%, respectively.

Conclusion: IMRT provides patients with non-metastatic NPC with satisfactory long-term survival. Both T stage and N stage are important prognostic factors for NPC patients. Patients with T4 or N3 diseases have significantly increased distant metastatic rates and poor survival time.

Citing Articles

Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.

Zheng Y, Xue F, Ou D, Niu X, Hu C, He X J Cancer Res Clin Oncol. 2025; 151(3):99.

PMID: 40035865 PMC: 11880137. DOI: 10.1007/s00432-025-06145-6.


Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.

Niu X, Xue F, Ou D, Zheng Y, Hu C, Shen C Int J Med Sci. 2025; 22(4):933-939.

PMID: 39991768 PMC: 11843132. DOI: 10.7150/ijms.105995.


The serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis.

Liu H, Lei L, Song S, Geng X, Lin K, Li N BMC Cancer. 2024; 24(1):1115.

PMID: 39244576 PMC: 11380781. DOI: 10.1186/s12885-024-12878-3.


Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non-metastatic stage T4 nasopharyngeal carcinoma in IMRT era.

Zheng Y, Xue F, Ou D, Niu X, Hu C, He X Cancer Med. 2024; 13(4):e6578.

PMID: 38457191 PMC: 10922019. DOI: 10.1002/cam4.6578.

References
1.
Kang M, Zhou P, Wei T, Zhao T, Long J, Li G . A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study. Am J Cancer Res. 2017; 7(2):346-356. PMC: 5336507. View

2.
Zhou Q, He Y, Zhao Y, Wang Y, Kuang W, Shen L . A Study of 358 Cases of Locally Advanced Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiation Therapy: Improving the Seventh Edition of the American Joint Committee on Cancer T-Staging System. Biomed Res Int. 2017; 2017:1419676. PMC: 5318629. DOI: 10.1155/2017/1419676. View